Über uns

À propos de nous

Open Access

Karriere

Carrière

Aboverträge Kündigen

Résiliation d’abonnement

Vertrag widerrufen

Résiliation de contrat 

Datenschutz

Protection des données

Impressum

Mentions légales

Barrierefreiheit

Accessibilité

Zahlung und Lieferung

Paiement et livraison

Libra

Was ist Libra?

C'est quoi Libra ?

Kostenlos testen

Tester gratuitement

LEXIA

LEXIA Arbeitsrecht

Was ist LEXIA?

C'est quoi LEXIA ?

LEXIA Familienrecht

Zeitschriften

Revues

recht

Pflegerecht

ZBJV

forumpoenale

ZStrR

Anwaltsrevue

Revue de l'avocat

RSAS

FamPra.ch

ASYL

Life Science Recht

BlAR

Sachbuch

Livres spécialisés

LOKI

Semaphor

Fokusthemen

Focus

Thema

Recht studieren

Arbeitsrecht

Droit du travail

Studium

Études

Familienrecht

Droit de la famille

Sozialversicherungsrecht

Droit des assurances sociales

Strafrecht

Droit pénal

Aktienrecht

Droit des sociétés anonymes

Persönlichkeitsrecht

Droit de la personnalité

Publikationen

Publications

Literatur

Digitales Angebot

Bücher

Livres

Buchreihen

Collections

Onlinemodule LEXIA

Modules en ligne LEXIA

recht.ch

Studienliteratur

Littérature pour les études

Swisslex

Dienstleistungen

Services

Dienstleistungen für

Corporate Books

Publishing Lösungen

Aktuelles

Geschäftskunden

Professionnels

Corporate Publishing

Content solutions

Buchhandlungen

Librairies

Veranstaltungen

Événements

Presse

Dozierende

Enseignants

Studierende

Étudiants

Inserierende

Annonceurs

Newsletter

Blog

Autorinnen/Autoren

Auteurs

Unsere Schreibenden

Hilfe

Unsere Autorinnen und Autoren

Liste

Autorenlounge

Espace des auteurs

Bei uns publizieren

Publier chez nous

Open Access Policy

Verlag

Éditions

Themen

Mehr wissen

Mitarbeitende

Collaborateurs

Geschichte

Histoire

Unser Magazin

Notre magazine

Vision und Mission

Vision et mission

Partner

Partenaires

Unternehmenskultur

Culture d'entreprise

Kontakt

Contact

Shop

Schweizer Recht

Ausländisches Recht

Über unseren Shop

Neuerscheinungen

Nouveautés

Sortiment & Suche

Catalogue & Recherche

Vorankündigungen

À paraître

Nach Rechtsgebiet

Par domaine juridique

Kommentare

Commentaires

Gesamtkatalog

Catalogue complet

Fachkatalog Recht

Catalogue de droit

Liam B: Pain, Tears and Dark Secrets of
Johnson Pharm & Cosmetics Company

Pain, Tears and Dark Secrets of Johnson Pharm & Cosmetics Company

Unveiling The Truth

"This book will not make it simple. It will make it more honest, more disciplined, and more likely to produce results that persist."- Professor the Lord Darzi of Denham, from the Foreword Healthcare transformation is failing. Decades of reform and billions in investment have left the $4.3 trillion US healthcare system and the NHS delivering declining outcomes, workforce burnout, and operational dysfunction. The programmes multiply. The results disappoint. The human cost is tangible: around the world, growing numbers of people are denied care that the knowledge and capability already exist to provide. That is a moral failure as much as a systemic one, and it is why this book was written. Anyone who has led one of those programmes knows the shape of it. The pilot works. The evaluation is positive. A year later the service is doing what it always did. Healthcare has been relentlessly improved. It has rarely been designed. That distinction is the subject of this book. The capability required is already in the building. The diagnostic reasoning of good clinical practice - deep observation, iterative refinement, solutions fitted to the specific situation - mirrors the design process precisely. Clinicians are already design thinkers. The challenge is unlocking what exists and directing it at the design of care systems, alongside the delivery of care. This is not a book of workshops, sticky notes and empathy maps. It is a framework and a field manual for the people accountable for change: healthcare executives, clinical directors, policymakers, and innovation leaders. Part IV diagnoses why transformation initiatives collapse - the structural traps, political dynamics, and institutional resistance that defeat even well-designed programmes. Part V supplies the tools, 90-day roadmaps, and a fully customised implementation field manual to begin immediately. Drawing on the author's nine years of medical training, eleven years as a professional designer at Michelotti and Jaguar, and twenty-five years teaching design thinking to engineering and business leaders, the book spans clinical trials, AI implementation, policy design, and organisational change.Equitable, sustainable, effective healthcare is within reach. Here is how to build it.

A Practical Guide to Healthcare Transformation

Design Thinking for Healthcare

The Indian Pharmaceutical Industry (IPI) has grown exponentially over the last few decades; however, recent global competition is forcing the industry to examine its performance focusing on productivity, efficiency and growth capabilities. While the industry as a whole has proved resilient to economic slowdowns, the performance of individual firms in the industry have displayed large disparities. There is also evidence of disparity among the Indian states. Efficiency and productivity act as good performance indicators. Performance Analysis of the Indian Pharmaceutical Industry estimates the extent of technical efficiency (TE) and total factor productivity growth (TFPG) of IPI and to identify their major affecting factors. A comparison between efficiency and TFPG of IPI is made, looking at the common factors responsible for variations in efficiency and TFPG of IPI. Chakraborty and Pal examine the import and export of Indian medicines to understand the place of the industry on a global scale and assess what can be done to become more competitive. The international comparison of this study will appeal and be useful for researchers, industry professionals and policy makers.

A Global Outlook

Performance Analysis of the Indian Pharmaceutical Industry

“The choice to invest in vaccines rather than in weapons; in treatments for rare diseases rather than in speculative consumer products; in long-term infrastructure rather than in short-term optics—these are not technical decisions. They are moral decisions . . .” Biotech in the Balance by Dr. Jeremy M. Levin shows why the next lifesaving medicines may not arrive on time, and what we can do about that in a period of political change. This is not a technical book. It is a bedside-to-boardroom story, told from inside the system, with a clear map of what has to change so that medicines keep arriving when people need them. When funding for research and development is politicized, trust in science erodes and the foundations of biotechnology weaken. When science is treated as a partisan symbol rather than a shared foundation for health, patients and families bear the consequences. Dr. Levin’s career began as a scientist studying the structure of DNA, and then as a physician in university hospitals in London, Cape Town, and Geneva. As a doctor, he saw the difference between patients saved by medicines that arrived just in time, and those who were not so fortunate. That experience led to a simple conviction: drug discovery and development is not an abstract business. It is a living coalition of scientists, governments, businesses, and—above all—patients. For patients and their families, profitability and internal strategy are not the point. What matters is whether a therapy works, how quickly results can be seen, and how benefits are weighed against risks—including the risk of doing nothing. Throughout the book, Dr. Levin keeps patients at the center of the discussion—politics, markets, supply chains, and governance—and shows how each of these forces can accelerate or delay medical progress. Written from the perspective of a scientist and physician, Biotech in the Balance argues for a resilient, globally competitive biotechnology industry built to serve patients and earn lasting public trust. It offers a call to action for preserving biotechnology as a strategic asset—and a practical framework for leaders who want to strengthen the system rather than merely defend it.

Saving a Strategic Industry in an Age of Distrust

Biotech in the Balance

Independently published

What happens behind the medicines we see on pharmacy shelves?The pharmaceutical industry is far bigger than pills, injections, and prescriptions. Behind every successful medicine is a vast ecosystem of research, diagnostics, clinical trials, manufacturing, testing, packaging, logistics, technology, and specialized services.Beyond the Pill takes you inside these lesser-known businesses and reveals how major pharmaceutical companies create value beyond the medicine itself.Inside this book, you'll discover: <ul><li>Hidden businesses operating around major pharmaceutical companies</li><li>Human plasma collection and processing</li><li>Diagnostics and personalized medicine</li><li>Clinical research and CROs</li><li>Contract manufacturing and CDMOs</li><li>Biotech and antibody discovery</li><li>Vaccine and cold-chain ecosystems</li><li>Drug delivery and pharmaceutical packaging</li><li>mRNA and biological manufacturing</li><li>Medical devices and specialty healthcare services</li><li>Practical entry points for smaller businesses and entrepreneurs</li><li>Indicative investment ranges and revenue models</li><li>Common problems, risks, and barriers to entry</li><li>Beginner strategies for entering the wider pharma ecosystem</li></ul>This book is not about becoming the next pharmaceutical giant. It is about learning to see the businesses surrounding the giants.For entrepreneurs, investors, professionals, and curious readers, Beyond the Pill offers a practical look at the hidden infrastructure that makes modern healthcare possible.Look beyond the medicine. Discover the business behind it.

The Business You Never See: Hidden Opportunities Behind Drugs, Diagnostics & Healthcare

Pharma

Lulu.com

Germa

Pharmakologische Erklärung für den beobachteten Geschlechtsunterschied bei der Erholung von der Anästhesie, Nk¿wa nke ngalaba ¿gw¿ ¿gw¿ nye ¿d¿iche nke nwoke na nwaany¿ nke a ch¿p¿tara na mgbake site n'anaesthesia Pharmakologie von Anästhetika 101

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's

Doctored

Fragen Sie sich auch, was eigentlich in unseren Gesundheitssystemen schiefläuft?
Fachkräftemangel, Krankenhausschwund, steigende Kosten und Zweiklassenmedizin?
Corona hat uns die schlimmste und die beste Facette gezeigt: 6 Millionen Coronatote, und 4 neue Impfstoffe in weniger als einem Jahr.
Dieses Buch ist definitiv für Sie, wenn Sie:Fakten und Argumente brauchen, die den Problemen auf den Grund gehen;
einen konstruktiven Beitrag zur Debatte leisten und nicht nur Schuldige suchen;
eine praktische Anleitung möchten, was jede und jeder tun kann;
und sich eine gute Medizin für alle wünschen: Patienten, ärzte, Kassen, Behörden, Industrie - den TangoForFive.

Kooperation und Wertschöpfung - Die Zukunft der Medizin

It Takes Five to Tango

The drug development process in the United States has become so weighted down by a business-as-usual paradigm that an average of more than $2 billion is spent to secure FDA approval for every new drug. Because the investment required is so extreme, drug development companies are understandably focused on discovering and developing drugs designed for large patient populations: diseases experienced by millions, such as high blood pressure, diabetes, or some of the more common cancers. In Unnecessary Expense, Dr. Charles Theuer, CEO of TRACON Pharmaceuticals, outlines the problem and offers a solution: an aligned and streamlined model that emphasizes quality and reduces the time and cost of drug development, while also harnessing global innovation to benefit patients with rare diseases in urgent need of new treatments. Here Dr. Theuer shows the value of a pharmaceutical paradigm shift, to enable the development of drugs for patients who need them, at a fraction of the time and cost.

An Antidote for the Billion Dollar Drug Problem

Unnecessary Expense

In what is a monumental and deeply impressive exploration of humanity's next chapter, Homo Sapiens 2.0 delivers a landmark analysis of the advent of self-directed evolution. This is not a simple overview of future technology, but a work of profound intellectual rigor and startling clarity that synthesizes complex science, cutting-edge philosophy, and pragmatic political analysis into a single, masterfully constructed narrative.
The book takes the reader on a systematic and unflinching journey. It begins by grounding us in the foundational tools of our new era-from the molecular scalpels of CRISPR to the cortical co-processors of neurotechnology. From there, it pivots to the staggering consequences, deconstructing the emergence of new social hierarchies, the chilling logic of the commodification of human traits, and the philosophical crises of identity and consciousness that arise when the human blueprint becomes editable text.
A hallmark of this work is its "speculative realism." Homo Sapiens 2.0 crafts vivid, chillingly plausible scenarios-from the birth of a new Martian subspecies adapted for extraterrestrial life to an earthbound "upgrade economy" that threatens to create a permanent biological underclass-that feel less like fiction and more like well-researched prophecy. Yet this stark vision is meticulously balanced. A robust defense of "The Right to Remain Natural" provides a crucial counterpoint to technological inevitability, framing resistance not as mere Luddism but as a vital political, spiritual, and ecological necessity.
Ultimately, Homo Sapiens 2.0 moves beyond diagnosis to prescription. It culminates in a powerful and pragmatic call for stewardship, proposing a detailed and credible framework for global governance-the "Human Specification Accord"-designed to navigate the treacherous ethical landscape ahead.
This is a challenging, essential, and urgently needed book, destined to shape policy and public discourse. It is a map of the new territory humanity is entering, charting not only the immense promise for flourishing but also the profound perils of a future left to chance. For anyone seriously engaged with the future of technology, ethics, and the human species, this is indispensable reading. Evolution, once a blind force, now awaits our command. This book is the guide to the choices that lie before us.

Engineering Our Future Through Radical Evolution

Homo Sapiens 2.0

Scale, Scope and Spillovers: The Determinants of Research Productivity in Ethical Drug Discovery

The global healthcare landscape is profoundly transformed, driven by technological advancements, demographic shifts, evolving patient expectations, and new economic paradigms.The New Health Economy explores how emerging innovations-such as artificial intelligence (AI), personalized medicine, digital health solutions, and value-based care-reshape healthcare delivery, costs, and accessibility. This book will provide a roadmap for leaders to navigate the future of healthcare while addressing challenges related to ethics, equity, regulation, and sustainability. Drawing upon cutting-edge research, expert insights, and real-world case studies, The New Health Economy presents a compelling vision of healthcare's future and the economic forces driving it. The book blends economic theory with practical solutions, demonstrating how key players-from government agencies and hospitals to startups and Big Tech-are redefining healthcare systems globally. The healthcare industry is at an inflexion point. Traditional models are struggling with rising costs, ageing populations, and the burden of chronic diseases. Meanwhile, innovations in digital health, data analytics, and biotechnology offer unprecedented opportunities to enhance patient outcomes and economic efficiency.This is a timely, research-backed book that provides a comprehensive, forward-thinking guide for navigating the rapid transformations in healthcare. By blending economic analysis with healthcare innovation, it offers readers an invaluable resource for understanding not just where healthcare is going, but how to shape its future.

Navigating Innovation, Equity, and the Future of Care

The New Health Economy

Single-Cell Omics: Volume 1: Technological Advances and Applications provides the latest technological developments and applications of single-cell technologies in the field of biomedicine. In the current era of precision medicine, the single-cell omics technology is highly promising due to its potential in diagnosis, prognosis and therapeutics. Sections in the book cover single-cell omics research and applications, diverse technologies applied in the topic, such as pangenomics, metabolomics, and multi-omics of single cells, data analysis, and several applications of single-cell omics within the biomedical field, for example in cancer, metabolic and neuro diseases, immunology, pharmacogenomics, personalized medicine and reproductive health. This book is a valuable source for bioinformaticians, molecular diagnostic researchers, clinicians and members of the biomedical field who are interested in understanding more about single-cell omics and its potential for research and diagnosis.

Volume 1: Technological Advances and Applications

Single-Cell Omics

Pain, Tears and Dark Secrets of Johnson Pharm & Cosmetics Company

Weitere Titel zum Thema